|
|
|
|
| LEADER |
01391nam a22002775i 4500 |
| 001 |
000291992 |
| 005 |
20210930105650.0 |
| 007 |
cr nn 008mamaa |
| 008 |
161107s2016 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319460918
|
| 024 |
7 |
|
|a 10.1007/978-3-319-46091-8
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Resistance to Tyrosine Kinase Inhibitors /
|c edited by Daniele Focosi.
|
| 250 |
|
|
|a 1st ed. 2016.
|
| 260 |
# |
# |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2016.
|
| 300 |
|
|
|a XIII, 188 p. 8 illus., 6 illus. in color. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics,
|
| 505 |
0 |
|
|a Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells -- Resistance to Tyrosine Kinase Inhibitors in different types of solid cancer -- The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview -- Resistance to FLT3 Inhibitors -- Resistance to ALK inhibitors -- Resistance to Angiokinase Inhibitors -- Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
1 |
4 |
|a Cancer Research.
|
| 700 |
1 |
|
|a Focosi, Daniele.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|